Q2 2025 Oncopeptides AB Earnings Call Transcript
Key Points
- Oncopeptides AB (STU:OND) reported a significant increase in net sales, reaching SEK19.2 million in Q2 2025, marking a 45% growth compared to Q1 and a 135% increase from the previous year.
- The company achieved three consecutive quarters of over 30% sales growth, demonstrating strong momentum in key European markets such as Germany, Spain, and Italy.
- Pepaxti has been included in the EHA and EMN guidelines, providing external validation and supporting its adoption in the treatment landscape.
- Oncopeptides AB is progressing with partnership discussions in Japan, with two non-binding offers received, indicating potential for expansion outside Europe.
- The company announced a rights issue of up to SEK150 million to ensure financial flexibility and support ongoing commercial operations, aiming for cash flow positivity by the end of 2026.
- Despite the growth in sales, Oncopeptides AB still requires additional financing to reach cash flow positivity, highlighting ongoing financial challenges.
- The company is experiencing delays in concluding a partnership deal in Japan, which was initially expected to contribute to cash flow positivity.
- Operating expenses, while stable, remain a concern as the company continues to manage costs carefully to maintain profitability targets.
- The rights issue indicates a need for significant capital infusion, which may dilute existing shareholders' equity.
- There is uncertainty regarding the exact timeline for closing the Japanese partnership deal, which could impact future revenue projections.
Hi everyone and welcome to the presentation of Oncopeptides's report for the second quarter of 2025. This is our standard disclaimer. I'm Sofia Heigis, CEO of Oncopeptides, and I'm joined by our CFO, Henrik Bergentoft, who will give a financial update in just a few minutes.
Let's start with the highlights from the quarter. Q2 was an eventful quarter, and we took strong steps forward in Europe. We reached net sales of SEK19.2 million. That's up 45% compared to Q1 and 135% versus last year. It's worth to point out that this is our third quarter in a row with more than 30% growth.
Germany continues to perform well. Spain and Italy has been moving faster than expected on regional access, and the positive clinical experience generated has already now been translated into real world publications that is supporting our launches. Momentum has carried into the summer too. Sales in July were 3 times higher than July last year. As August is a vacation period in most of Europe, we believe a strong July to be especially important.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
